DEGNAN CHRIS (Chief Financial Officer) sold 49.1% of their position (2.20K shares) of UROGEN PHARMA LTD. on the open market
Open‑market sale worth $37.1K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 10/9/2025ACC: 0001437749-25-030772
Officer· Chief Financial Officer
Since Jan 2026
-2.20K
Net shares
Net seller
$37.1K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
4.48K acquired · 6.69K disposed
Non-Derivative Transactions2
Ordinary Shares
Direct
Shares
+4.48K
Price / share
—
Trade value
—
% of position
New position
10/8/2025
0.00→4.48K
Ordinary Shares
Direct
Shares
−2.20K
Price / share
$16.85
Trade value
$37.12K
% of position
49.1%
10/8/2025
4.48K→2.28K
Total
Net shares
+2.28K
Net value
-$37.12K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Direct | 10/8/2025 | M · Option Exercise | +4.48K | — | — | New position | 0.00 | 4.48K |
| Ordinary Shares Direct | 10/8/2025 | S · Sale | −2.20K | $16.85 | $37.12K | 49.1% | 4.48K | 2.28K |
| Total | +2.28K | -$37.12K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Ordinary Shares
4.48K shares
Shares
−4.48K
Strike price
Held after
8.97K
Exercisable
—
10/8/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Ordinary Shares4.48K shares | 10/8/2025 | M · Option Exercise | −4.48K | — | 8.97K |